{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:09:56Z","timestamp":1740107396523,"version":"3.37.3"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T00:00:00Z","timestamp":1543536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000837","name":"University of Nottingham","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000837","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00330-018-5788-1","type":"journal-article","created":{"date-parts":[[2018,11,30]],"date-time":"2018-11-30T05:43:04Z","timestamp":1543556584000},"page":"3100-3107","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Short-term changes observed in multiparametric liver MRI following therapy with direct-acting antivirals in chronic hepatitis C virus patients"],"prefix":"10.1007","volume":"29","author":[{"given":"C.","family":"Bradley","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. A.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cox","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Palaniyappan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B. J.","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. D.","family":"Ryder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. L.","family":"Irving","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. P.","family":"Aithal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. N.","family":"Guha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,11,30]]},"reference":[{"key":"5788_CR1","doi-asserted-by":"crossref","unstructured":"Polaris Observatory HCV Collaborators (2017) Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol 2:161\u2013176","DOI":"10.1016\/S2468-1253(16)30181-9"},{"key":"5788_CR2","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1056\/NEJMoa1402454","volume":"370","author":"N Afdhal","year":"2014","unstructured":"Afdhal N, Zeuzem S, Kwo P et al (2014) Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med 370:1889\u20131898","journal-title":"N Engl J Med"},{"key":"5788_CR3","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa1402869","volume":"370","author":"F Poordad","year":"2014","unstructured":"Poordad F, Hezode C, Trinh R et al (2014) ABT-450\/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med 370:1973\u20131982","journal-title":"N Engl J Med"},{"key":"5788_CR4","doi-asserted-by":"publisher","first-page":"1756","DOI":"10.1016\/S0140-6736(14)61036-9","volume":"384","author":"E Lawitz","year":"2014","unstructured":"Lawitz E, Sulkowski MS, Ghalib R et al (2014) Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet 384:1756\u20131765","journal-title":"Lancet"},{"key":"5788_CR5","doi-asserted-by":"crossref","unstructured":"Foster GR, Irving WL, Cheung MC et al (2016) Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 64:1224\u20131231","DOI":"10.1016\/j.jhep.2016.01.029"},{"key":"5788_CR6","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL et al (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149:649\u2013659","journal-title":"Gastroenterology"},{"key":"5788_CR7","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1002\/hep.27766","volume":"62","author":"HA Innes","year":"2015","unstructured":"Innes HA, McDonald SA, Dillon JF et al (2015) Toward a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology 62:355\u2013364","journal-title":"Hepatology"},{"key":"5788_CR8","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1053\/j.gastro.2016.09.009","volume":"152","author":"P Nahon","year":"2017","unstructured":"Nahon P, Bourcier V, Layese R et al (2017) Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152:142\u2013156 e142","journal-title":"Gastroenterology"},{"key":"5788_CR9","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1002\/hep.23744","volume":"52","author":"TR Morgan","year":"2010","unstructured":"Morgan TR, Ghany MG, Kim HY et al (2010) Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology 52:833\u2013844","journal-title":"Hepatology"},{"key":"5788_CR10","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1002\/hep.25606","volume":"56","author":"R D\u2019Ambrosio","year":"2012","unstructured":"D\u2019Ambrosio R, Aghemo A, Rumi MG et al (2012) A morphometric and immunohistochemical study to assess the benefit of a sustained virological response in hepatitis C virus patients with cirrhosis. Hepatology 56:532\u2013543","journal-title":"Hepatology"},{"key":"5788_CR11","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.humpath.2003.08.012","volume":"35","author":"S Pol","year":"2004","unstructured":"Pol S, Carnot F, Nalpas B et al (2004) Reversibility of hepatitis C virus-related cirrhosis. Hum Pathol 35:107\u2013112","journal-title":"Hum Pathol"},{"key":"5788_CR12","doi-asserted-by":"publisher","first-page":"399","DOI":"10.7326\/0003-4819-149-6-200809160-00006","volume":"149","author":"V Mallet","year":"2008","unstructured":"Mallet V, Gilgenkrantz H, Serpaggi J et al (2008) Brief communication: the relationship of regression of cirrhosis to outcome in chronic hepatitis C. Ann Intern Med 149:399\u2013403","journal-title":"Ann Intern Med"},{"key":"5788_CR13","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/hep.22694","volume":"49","author":"SL George","year":"2009","unstructured":"George SL, Bacon BR, Brunt EM, Mihindukulasuriya KL, Hoffmann J, Di Bisceglie AM (2009) Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients. Hepatology 49:729\u2013738","journal-title":"Hepatology"},{"key":"5788_CR14","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1053\/gast.2002.33023","volume":"122","author":"T Poynard","year":"2002","unstructured":"Poynard T, McHutchison J, Manns M et al (2002) Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C. Gastroenterology 122:1303\u20131313","journal-title":"Gastroenterology"},{"key":"5788_CR15","doi-asserted-by":"publisher","first-page":"g7809","DOI":"10.1136\/bmj.g7809","volume":"350","author":"RL Koretz","year":"2015","unstructured":"Koretz RL, Lin KW, Ioannidis JP, Lenzer J (2015) Is widespread screening for hepatitis C justified? BMJ 350:g7809","journal-title":"BMJ"},{"key":"5788_CR16","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1136\/gut.50.3.425","volume":"50","author":"AK Burroughs","year":"2002","unstructured":"Burroughs AK, Groszmann R, Bosch J et al (2002) Assessment of therapeutic benefit of antiviral therapy in chronic hepatitis C: is hepatic venous pressure gradient a better end point? Gut 50:425\u2013427","journal-title":"Gut"},{"key":"5788_CR17","doi-asserted-by":"publisher","first-page":"2269","DOI":"10.1111\/j.1572-0241.2006.00743.x","volume":"101","author":"D Rincon","year":"2006","unstructured":"Rincon D, Ripoll C, Lo Iacono O et al (2006) Antiviral therapy decreases hepatic venous pressure gradient in patients with chronic hepatitis C and advanced fibrosis. Am J Gastroenterol 101:2269\u20132274","journal-title":"Am J Gastroenterol"},{"key":"5788_CR18","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.cgh.2007.02.022","volume":"5","author":"S Roberts","year":"2007","unstructured":"Roberts S, Gordon A, McLean C et al (2007) Effect of sustained viral response on hepatic venous pressure gradient in hepatitis C-related cirrhosis. Clin Gastroenterol Hepatol 5:932\u2013937","journal-title":"Clin Gastroenterol Hepatol"},{"key":"5788_CR19","doi-asserted-by":"publisher","unstructured":"Lens S, Alvarado-Tapias E, Mari\u00f1o Z et al (2017) Effects of all-oral anti-viral therapy on HVPG and systemic hemodynamics in patients with hepatitis C virus-associated cirrhosis. Gastroenterology. \n                    https:\/\/doi.org\/10.1053\/j.gastro.2017.07.016","DOI":"10.1053\/j.gastro.2017.07.016"},{"key":"5788_CR20","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","volume":"59","author":"R D\u2019Ambrosio","year":"2013","unstructured":"D\u2019Ambrosio R, Aghemo A, Fraquelli M et al (2013) The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response. J Hepatol 59:251\u2013256","journal-title":"J Hepatol"},{"key":"5788_CR21","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1002\/nbm.3299","volume":"28","author":"CL Hoad","year":"2015","unstructured":"Hoad CL, Palaniyappan N, Kaye P et al (2015) A study of T(1) relaxation time as a measure of liver fibrosis and the influence of confounding histological factors. NMR Biomed 28:706\u2013714","journal-title":"NMR Biomed"},{"key":"5788_CR22","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1080\/00365521.2016.1233578","volume":"52","author":"S Agrawal","year":"2017","unstructured":"Agrawal S, Hoad CL, Francis ST, Guha IN, Kaye P, Aithal GP (2017) Visual morphometry and three non-invasive markers in the evaluation of liver fibrosis in chronic liver disease. Scand J Gastroenterol 52:107\u2013115","journal-title":"Scand J Gastroenterol"},{"key":"5788_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.jhep.2013.09.002","volume":"60","author":"R Banerjee","year":"2014","unstructured":"Banerjee R, Pavlides M, Tunnicliffe EM et al (2014) Multiparametric magnetic resonance for the non-invasive diagnosis of liver disease. J Hepatol 60:69\u201377","journal-title":"J Hepatol"},{"key":"5788_CR24","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.jhep.2016.07.021","volume":"65","author":"N Palaniyappan","year":"2016","unstructured":"Palaniyappan N, Cox E, Bradley C et al (2016) Non-invasive assessment of portal hypertension using quantitative magnetic resonance imaging. J Hepatol 65:1131\u20131139","journal-title":"J Hepatol"},{"key":"5788_CR25","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/jmri.23606","volume":"36","author":"AM Chow","year":"2012","unstructured":"Chow AM, Gao DS, Fan SJ et al (2012) Measurement of liver T(1) and T(2) relaxation times in an experimental mouse model of liver fibrosis. J Magn Reson Imaging 36:152\u2013158","journal-title":"J Magn Reson Imaging"},{"key":"5788_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.21037\/qims.2016.03.02","volume":"6","author":"AR Guimaraes","year":"2016","unstructured":"Guimaraes AR, Siqueira L, Uppal R et al (2016) T2 relaxation time is related to liver fibrosis severity. Quant Imaging Med Surg 6:103\u2013114","journal-title":"Quant Imaging Med Surg"},{"key":"5788_CR27","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1002\/jmri.22807","volume":"35","author":"SW Anderson","year":"2012","unstructured":"Anderson SW, Jara H, Ozonoff A, O\u2019Brien M, Hamilton JA, Soto JA (2012) Effect of disease progression on liver apparent diffusion coefficient and T2 values in a murine model of hepatic fibrosis at 11.7 Tesla MRI. J Magn Reson Imaging 35:140\u2013146","journal-title":"J Magn Reson Imaging"},{"key":"5788_CR28","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.jhep.2015.10.009","volume":"64","author":"M Pavlides","year":"2016","unstructured":"Pavlides M, Banerjee R, Sellwood J et al (2016) Multiparametric magnetic resonance imaging predicts clinical outcomes in patients with chronic liver disease. J Hepatol 64:308\u2013315","journal-title":"J Hepatol"},{"key":"5788_CR29","doi-asserted-by":"publisher","unstructured":"Bradley CR, Cox EF, Scott RA et al (2018) Multi organ assessment of compensated cirrhosis patients using quantitative magnetic resonance imaging. J Hepatol. \n                    https:\/\/doi.org\/10.1016\/j.jhep.2018.05.037","DOI":"10.1016\/j.jhep.2018.05.037"},{"key":"5788_CR30","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jhep.2016.06.019","volume":"65","author":"MC Cheung","year":"2016","unstructured":"Cheung MC, Walker AJ, Hudson BE et al (2016) Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol 65:741\u2013747","journal-title":"J Hepatol"},{"key":"5788_CR31","doi-asserted-by":"publisher","first-page":"602","DOI":"10.5152\/balkanmedj.2016.151082","volume":"33","author":"NI Gurcan","year":"2016","unstructured":"Gurcan NI, Sak\u00e7\u0131 Z, Akhan S et al (2016) Liver apparent diffusion coefficient changes during telaprevir-based therapy for chronic hepatitis C. Balkan Med J 33:602\u2013606","journal-title":"Balkan Med J"},{"key":"5788_CR32","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1007\/s10620-006-9143-z","volume":"52","author":"C Aube","year":"2007","unstructured":"Aube C, Moal F, Oberti F et al (2007) Diagnosis and measurement of liver fibrosis by MRI in bile duct ligated rats. Dig Dis Sci 52:2601\u20132609","journal-title":"Dig Dis Sci"},{"key":"5788_CR33","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1016\/j.jhep.2004.03.007","volume":"40","author":"VJ Desmet","year":"2004","unstructured":"Desmet VJ, Roskams T (2004) Cirrhosis reversal: a duel between dogma and myth. J Hepatol 40:860\u2013867","journal-title":"J Hepatol"},{"key":"5788_CR34","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1111\/apt.13844","volume":"45","author":"P Schwabl","year":"2017","unstructured":"Schwabl P, Mandorfer M, Steiner S et al (2017) Interferon-free regimens improve portal hypertension and histological necroinflammation in HIV\/HCV patients with advanced liver disease. Aliment Pharmacol Ther 45:139\u2013149","journal-title":"Aliment Pharmacol Ther"},{"key":"5788_CR35","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1002\/hep.29557","volume":"67","author":"E Mauro","year":"2018","unstructured":"Mauro E, Crespo G, Montironi C et al (2018) Portal pressure and liver stiffness measurements in the prediction of fibrosis regression after sustained virological response in recurrent hepatitis C. Hepatology 67:1683\u20131694","journal-title":"Hepatology"},{"key":"5788_CR36","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1111\/liv.13256","volume":"37","author":"JA Bachofner","year":"2017","unstructured":"Bachofner JA, Valli PV, Kr\u00f6ger A et al (2017) Direct antiviral agent treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers fibrosis-4 score and aspartate aminotransferase-platelet ratio index. Liver Int 37:369\u2013376","journal-title":"Liver Int"},{"key":"5788_CR37","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1111\/jvh.12578","volume":"23","author":"V Knop","year":"2016","unstructured":"Knop V, Hoppe D, Welzel T et al (2016) Regression of fibrosis and portal hypertension in HCV-associated cirrhosis and sustained virologic response after interferon-free antiviral therapy. J Viral Hepat 23:994\u20131002","journal-title":"J Viral Hepat"},{"key":"5788_CR38","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","volume":"59","author":"T Poynard","year":"2013","unstructured":"Poynard T, Moussalli J, Munteanu M et al (2013) Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C. J Hepatol 59:675\u2013683","journal-title":"J Hepatol"},{"key":"5788_CR39","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3851\/IMP2349","volume":"17","author":"T Reiberger","year":"2012","unstructured":"Reiberger T, Payer BA, Ferlitsch A et al (2012) A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. Antivir Ther 17:1327\u20131334","journal-title":"Antivir Ther"},{"key":"5788_CR40","doi-asserted-by":"publisher","unstructured":"Afdhal N, Everson GT, Calleja JL et al (2017) Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension. J Viral Hepat. \n                    https:\/\/doi.org\/10.1111\/jvh.12706","DOI":"10.1111\/jvh.12706"},{"key":"5788_CR41","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","volume":"65","author":"M Mandorfer","year":"2016","unstructured":"Mandorfer M, Kozbial K, Schwabl P et al (2016) Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. J Hepatol 65:692\u2013699","journal-title":"J Hepatol"},{"key":"5788_CR42","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1038\/ajg.2012.137","volume":"107","author":"C Morishima","year":"2012","unstructured":"Morishima C, Shiffman ML, Dienstag JL et al (2012) Reduction in hepatic inflammation is associated with less fibrosis progression and fewer clinical outcomes in advanced hepatitis C. Am J Gastroenterol 107:1388\u20131398","journal-title":"Am J Gastroenterol"},{"key":"5788_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1148\/radiol.10091295","volume":"256","author":"M Ronot","year":"2010","unstructured":"Ronot M, Asselah T, Paradis V et al (2010) Liver fibrosis in chronic hepatitis C virus infection: differentiating minimal from intermediate fibrosis with perfusion CT. Radiology 256:135\u2013142","journal-title":"Radiology"},{"key":"5788_CR44","doi-asserted-by":"publisher","first-page":"e0155967","DOI":"10.1371\/journal.pone.0155967","volume":"11","author":"R D\u2019Ambrosio","year":"2016","unstructured":"D\u2019Ambrosio R, Degasperi E, Aghemo A et al (2016) Serological tests do not predict residual fibrosis in hepatitis C cirrhotics with a sustained virological response to interferon. PLoS One 11:e0155967","journal-title":"PLoS One"},{"key":"5788_CR45","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1016\/S1665-2681(19)30840-3","volume":"13","author":"ML Shiffman","year":"2014","unstructured":"Shiffman ML, Sterling RK, Contos M et al (2014) Long term changes in liver histology following treatment of chronic hepatitis C virus. Ann Hepatol 13:340\u2013349","journal-title":"Ann Hepatol"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00330-018-5788-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-018-5788-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T19:07:46Z","timestamp":1575054466000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00330-018-5788-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,30]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["5788"],"URL":"https:\/\/doi.org\/10.1007\/s00330-018-5788-1","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"type":"print","value":"0938-7994"},{"type":"electronic","value":"1432-1084"}],"subject":[],"published":{"date-parts":[[2018,11,30]]},"assertion":[{"value":"11 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The scientific guarantor of this publication is Professor Susan Francis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was obtained from all subjects (patients) in this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"The HCV MRI study received ethical approval by the NRES Committee East Midlands - Derby 1 (Research Ethics Committee reference 11\/EM\/0314).","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 Prospective\u2022 Observational\u2022 Performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}